Opendata, web and dolomites

MEISi SIGNED

Druggable Small Molecule Inhibitor of MEIS Proteins

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEISi project word cloud

Explore the words cloud of the MEISi project. It provides you a very rough idea of what is the project "MEISi" about.

pending    3b    critical    deadliest    cardiovascular    published    pharmaceutically    first    cancer    tools    hoxa9    plays    tech    ending    efforts    prestigious    10m    sizes    nature    regulations    29    proteins    molecular    conduct    metabolism    pbx    risk    startup    active    massive    diseases    cell    meinox    modulate    therapeutics    ingredients    noncommunicable    protein    ncds    diabetes    channels    deaths    globally    stem    cvds    inhibitors    2018    significance    pct    co    meisi    class    biology    innovative    usd    owing    substance    nearly    competitive    market    performing    selective    indicate    meis    never    national    validated    molecule    tackling    global    customers    motivates    inhibits    countries    discovery    druggable    patented    drug    feasibility    oncology    markets    deep    entry    strategy    journals    commercialization    segment    44    71    mechanisms    benchmarking    plan    benefit    strategies    tgif2    share    family    accounting    small    company    proper   

Project "MEISi" data sheet

The following table provides information about the project.

Coordinator
MEINOX ILAC TEKNOLOJILERI AS 

Organization address
address: RESITPASA MAH. KATAR CAD. TEKNOKENT ARI 1 NO: 2/5 ICKAPI NO: 19
city: SARIYER ISTANBUL
postcode: 34467
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Turkey [TR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEINOX ILAC TEKNOLOJILERI AS TR (SARIYER ISTANBUL) coordinator 50˙000.00

Map

 Project objective

MEISi is the first innovative product of Meinox as a druggable substance, owing to its years of research on MEIS biology (published in prestigious journals like Nature and Cell Stem Cell, and PCT patented - pending national entry in 44 countries). Meinox targets the deadliest noncommunicable diseases (NCDs); cancer, CVDs and diabetes, together accounting for nearly 71% of all deaths globally. Never ending efforts and global targets in tackling these diseases show the importance of the development of more effective therapeutics.

MEISi is a druggable target-based small molecule, developed and validated by Meinox. MEISi inhibits the activity of MEIS protein which plays a critical role in cell metabolism and associated with NCDs. The benefit it presents to the targeted drug discovery market is to provide tools to modulate molecular mechanisms of the NCDs. The massive sizes of oncology and cardiovascular drug markets (USD $ 29.3B globally) indicate the significance of the small molecule drug discovery market which motivates Meinox to target €10M market share in 3 years after commercialization.

Meinox is a deep-tech startup established in 2018 with the main focus on novel and high-level pharmaceutically active ingredients. The company aims to research, develop, produce and market first-in-class, selective drug-like small molecule inhibitors of MEIS, PBX and TGIF2 proteins and their co-factor HOXA9.

Meinox aims to conduct a feasibility study with a risk analysis based on different market regulations. In order to improve the commercialization plan, potential customers of MEISi will be identified and strategies will be developed for each segment by defining proper channels for the MEISi product family. Market entry strategy will be validated by performing market analysis and competitive benchmarking in the target markets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEISI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEISI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

CyreenApplication (2019)

Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.

Read More